CAI
Caris Life Sciences, Inc.
There isn't enough reported data to score CAI yet.
CAI Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Stable | |
| Strong |
CAI's revenue and balance sheet are currently healthy, and its profitability and cash flow are stable.
CAI PE Valuation
CAI has no meaningful PE right now: it lost money over the past year.
CAI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for CAI, with profitability improving. However, they disagree widely on these estimates.
CAI Earnings Per Share
CAI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $275.4M | +27% |
| Q2 2026 | $263.7M | +45% |
| Q1 2026 | $216.2M | +79% |
| Q4 2025 | $292.9M | +125% |
| Q3 2025 | $216.8M | +113% |
| Q2 2025 | $181.4M | +81% |
| Q1 2025 | $120.9M | +50% |
| Q3 2021 | $100.8M | +28% |
CAI's revenue has grown year over year for 13 quarters in a row: $275M last quarter, up 27% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7% | -8 points |
| Q2 2026 | 10% | +20 points |
| Q1 2026 | 2.4% | +50 points |
| Q4 2025 | 30% | +59 points |
| Q3 2025 | 15% | +75 points |
| Q2 2025 | -9.9% | -77 points |
| Q1 2025 | -48% | +66 points |
| Q4 2024 | -29% | -94 points |
CAI's operating margin was 7% last quarter, down 8 points from the same quarter a year ago.
CAI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.7M | -172% |
| Q1 2026 | $22.5M | +$56.6M |
| Q4 2025 | $39.7M | +$80.9M |
| Q3 2025 | $55.3M | +$126.6M |
| Q1 2025 | -$34M | +$41.6M |
| Q3 2021 | -$447.6M | -895% |
| Q2 2021 | -$18.8M | -131% |
| Q1 2021 | -$95.9M | -397% |
CAI's free cash flow has turned positive after three years mostly in the red: $29M over the past year.
CAI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.3% | +12.3M shares |
| 1 year | +355% | +230M shares |
CAI has 295M diluted shares, up 355% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $10M |
| Q2 2026 | $21.4M |
| Q1 2026 | — |
| Q4 2025 | $91,000 |
| Q3 2025 | — |
| Q1 2025 | $22,000 |
| Q4 2024 | — |
| Q3 2024 | — |
CAI spent $31M buying back its own shares over the past year.
CAI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -3.4x | Net Cash |
| Q4 2025 | -11.6x | Net Cash |
| Q3 2021 | 7.5x | High |
| Q2 2021 | 6.5x | High |
| Q1 2021 | 6.2x | High |
| Q4 2020 | 6.7x | High |
| Q3 2020 | 9.6x | High |
| Q2 2020 | 8.5x | High |
CAI has more cash than debt.
CAI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 51.8 | Neutral |
CAI's weekly RSI is 48 (neutral) and its Stochastic is 52 (neutral).
CAI PE vs Healthcare Sector
CAI has no meaningful PE right now: it lost money over the past year.
CAI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.5 | 19% below |
| 20 week MA | $24.7 | 3.2% below |
| 50 week MA | $22.5 | 6.7% above |
CAI has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 6.7% above its 50-week average.
CAI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $27.3 | $28.2 | +3.6% |
| 2026 YTD | $28.2 | $24.0 | -15% |
CAI has finished every year since 2025 higher, and it's down 15% so far in 2026.